跳至主要内容
临床试验/NCT03621475
NCT03621475已完成1 期

Pilot Study of a Novel Arm Restraint For Critically Ill Patients

University of Vermont1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2018年10月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
8
试验地点
1
主要终点
Number of Treatment-Emergent Severe Adverse Events [Safety]

研究概览

简要总结

The goal of this pilot is to evaluate a novel restraint device in 8 older mechanically ventilated patients to demonstrate that 1) the revised novel restraint prototype is safe and 2) a future randomized controlled trial (RCT) is feasible.

详细描述

The goal of this Fast-Track Small Business Technology Transfer (STTR) project is to optimize and test a novel arm restraint in older critically ill mechanically ventilated patients that may increase mobility; reduce agitation, use of sedative medications, and delirium; and exhibit high satisfaction and acceptability among hospital staff, family members, and patients. Older mechanically ventilated patients are often immobilized with wrist restraints to prevent self-extubation and are sedated to reduce agitation caused by their restraints and endotracheal (breathing) tube. This sedation and immobility lead to complications, including delirium and muscle weakness, that are independently associated with long term cognitive impairment, reduced physical functioning, and mortality. Specifically, the incidence and duration of delirium in the ICU are strongly and independently associated with long-term cognitive impairment that is similar to Alzheimer's Disease and Related Dementias.

Healthy Design has developed a novel restraint device that allows arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines. Because it permits mobility, the novel restraint may reduce agitation and the need for sedatives. The objectives of this pilot study are to evaluate the novel restraint in 8 older mechanically ventilated patients to demonstrate that 1) the revised novel restraint prototype is safe and 2) a future RCT is feasible.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
None

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •>65 years old
  • •Physician order for use of bilateral wrist restraints
  • •Requiring mechanical ventilation with actual or expected total duration of >48 hours
  • •Expected ICU stay >3 days after enrollment (to permit adequate exposure to proposed intervention)
  • •Not deeply sedated (Richmond Agitation Sedation Scale [RASS] score > -2)

排除标准

  • •Upper extremity impairments that prevent use of novel restraint device (e.g. amputation, arm injury)
  • •Limited mobility of either upper extremity prior to admission (e.g. frozen shoulder, severe arthritis)
  • •Pre-existing primary systemic neuromuscular disease (e.g. Guillain-Barre)
  • •Neuromuscular blocker infusion (eligible once infusion discontinued if other inclusion criteria met)
  • •Pre-existing severe cognitive impairment or language barrier prohibiting outcome assessment
  • •Expected death or withdrawal of life-sustaining treatments within 6 days from enrollment
  • •Incarcerated
  • •Severe skin breakdown on either upper extremity

研究组 & 干预措施

Novel restraint first, then traditional restraint

Experimental

Participants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.

干预措施: Novel restraint (Device)

Traditional restraint first, then novel restraint

Experimental

Participants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.

干预措施: Novel restraint (Device)

结局指标

主要结局

Number of Treatment-Emergent Severe Adverse Events [Safety]

时间窗: Through study day 2

Safety will be measured by the number (i.e. \< 1 in 5 participants had a treatment emergent safety event per their on study time) across all of the following measures listed below. Incidence does not have to be per person-year; in this case it is incidence of safety adverse event during the study period.

Number of Clinician or Patient Lacerations

时间窗: Through study day 2

Grade 2b or higher skin laceration (per Skin Tear Audit Research \[STAR\] Skin Tear Classification System) in patient or clinician from any sharp edges of device. The STAR grading system ranges from grade 1a at best to 3 at worst. Each laceration is given an individual score based on appearance.

Number of Pressure Ulcers From Device

时间窗: Through study day 2

Development of pressure ulcer from device of Stage 3 or greater per 2016 National Pressure Ulcer Advisory Panel Pressure Injury Stages. This staging system provides an individual score to each pressure ulcer based on appearance from stage 1 (best) to stage 4 (worst)

Number of Self-removals of Novel Restraint

时间窗: Through study day 2

Self-removal of novel restraint

Number of Damaging Events to Hospital Bed Rendering it Non-functional

时间窗: Through study day 2

Any damage to hospital bed from restraint device rendering it non-functional

Number of Damaging Events to ICU Equipment

时间窗: Through study day 2

Any damage to ICU equipment (e.g. ventilator) rendering it non-functional

次要结局

  • Number of Movements of Upper Extremities(Continuously through study day 2)
  • Number of Self-extubations(Through study day 2)
  • Richmond Agitation Sedation Score [RASS](Median of multiple RASS scores collected over first 2 days of study period)
  • Satisfaction With Novel Device as Assessed by the Quebec User Evaluation of Satisfaction With Assistive Technology (QUEST) Satisfaction Score(Study day 2)
  • Delerium Score(6-day study period)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Renee Stapleton

Associate Professor of Medicine

University of Vermont

研究点 (1)

Loading locations...

相似试验